Nano Precision Medical
Vivani Medical is an innovative, near-clinical stage biopharmaceutical company leveraging proprietary NanoPortal™ platform technology to develop miniature, long-term drug implants. Their mission is to address medication non-adherence and tolerability in chronic disease treatment by creating minimally invasive, extended-release implants that deliver steady doses of medication over months, improving patient outcomes and reducing healthcare costs.
Industries
Nr. of Employees
small (1-50)
Nano Precision Medical
1350 S. Loop Road, Alameda, CA 94502, USA
Patents
Products
Six-month subdermal GLP-1 implant for chronic weight management
A miniature subdermal implant designed to deliver a high-dose GLP-1 receptor agonist continuously for at least six months to support chronic weight management and reduce reliance on frequent injections or daily pills.
Six-month subdermal GLP-1 implant for type 2 diabetes
A miniature subdermal implant designed to deliver a GLP-1 receptor agonist continuously for at least six months to support treatment of type 2 diabetes and reduce dosing burden.
Preclinical semaglutide implant candidate (obesity)
An investigational semaglutide-based implant candidate in preclinical development intended for long-duration delivery for obesity indications.
Six-month subdermal GLP-1 implant for feline diabetes (veterinary)
A miniature implant developed in collaboration with a veterinary partner to deliver GLP-1 therapy to cats for at least six months, intended to reduce administration stress on owners and animals.
Targeted neurostimulation systems (subsidiary-developed)
Neurostimulation devices combining microelectronics, embedded software and data processing intended for applications such as artificial vision and functional recovery after stroke.
Six-month subdermal GLP-1 implant for chronic weight management
A miniature subdermal implant designed to deliver a high-dose GLP-1 receptor agonist continuously for at least six months to support chronic weight management and reduce reliance on frequent injections or daily pills.
Six-month subdermal GLP-1 implant for type 2 diabetes
A miniature subdermal implant designed to deliver a GLP-1 receptor agonist continuously for at least six months to support treatment of type 2 diabetes and reduce dosing burden.
Preclinical semaglutide implant candidate (obesity)
An investigational semaglutide-based implant candidate in preclinical development intended for long-duration delivery for obesity indications.
Six-month subdermal GLP-1 implant for feline diabetes (veterinary)
A miniature implant developed in collaboration with a veterinary partner to deliver GLP-1 therapy to cats for at least six months, intended to reduce administration stress on owners and animals.
Targeted neurostimulation systems (subsidiary-developed)
Neurostimulation devices combining microelectronics, embedded software and data processing intended for applications such as artificial vision and functional recovery after stroke.
Services
Collaborative development of miniaturized subdermal implants tailored to specific drug molecules, dosing rates and treatment durations using configurable nanotube membranes and reservoir design.
Design and execution of preclinical efficacy studies and pharmacokinetic evaluations intended to support translation of implant-based delivery from animal models to human clinical trials.
Planning and conducting early-phase clinical studies for subdermal implant programs, including multi-center first-in-human trials to evaluate safety, PK and preliminary outcomes.
Collaborative development of miniaturized subdermal implants tailored to specific drug molecules, dosing rates and treatment durations using configurable nanotube membranes and reservoir design.
Design and execution of preclinical efficacy studies and pharmacokinetic evaluations intended to support translation of implant-based delivery from animal models to human clinical trials.
Planning and conducting early-phase clinical studies for subdermal implant programs, including multi-center first-in-human trials to evaluate safety, PK and preliminary outcomes.
Expertise Areas
- Implantable drug delivery development
- Nanotube membrane fabrication and materials
- Peptide/protein therapeutic delivery
- Preclinical pharmacology and efficacy testing
Key Technologies
- Subdermal reservoir implants
- Nanotube-based diffusion membranes
- Peptide and protein delivery
- Microfabrication on metal substrates